Under scanner:
- National Pharmaceutical Pricing Authority (NPPA) has observed that many companies in India are flouting pricing norms by introducing drugs without its approval
- NPPA's list comprises 200-odd drugs, including fixed-dose combinations (FDCs), and all major pharmaceutical companies
- NPPA says It is not clear whether these formulations have the approval of Central Drugs Standard Control Organisation
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in